爱尔眼科2025年年度报告深度解读：数字化与AI驱动转型，净利润承压但核心业务稳健增长

一、报告要点概览

• 营业收入同比增长6.53%，但归母净利润同比下降8.88%
• 数字化与AI战略全面推进，AI产品矩阵和医疗大数据开发实现突破
• 门诊量和手术量持续增长，“分级连锁”模式深化，海外业务布局扩展
• 利润分配预案：每10股派发现金红利1元（含税）
• 组织架构与人才结构优化，合并省区，成立管理委员会，提高运营效率
• 多项行业首创与创新成果获奖，行业地位显著提升

二、核心业绩与财务表现

2025年，爱尔眼科实现营业收入223.53亿元，同比增长6.53%；门诊量1,889.17万人次，同比增长11.52%；手术量168万例，同比增长5.77%。尽管主营业务持续增长，但归属于母公司的净利润为32.40亿元，同比下降8.88%；归属于母公司扣除非经常性损益的净利润为31.41亿元，同比增长1.36%。
经营活动现金流净额59.73亿元，同比增长22.35%。总资产达366.76亿元，同比增长10.29%；归属于上市公司股东的净资产219.74亿元，同比增长6.08%。
分季度来看，第四季度归母净利润大幅下降，显示成本控制和利润释放面临挑战，值得投资者关注。

三、战略转型与创新布局

1. 数字化与AI创新——业绩新驱动

公司持续加大数字化和AI创新投入，已建成“爱尔AI眼科医院”，核心产品如“AI眼底影像辅助诊断系统”累计调用超60万次，眼睑肿物智能筛查系统检测超3万张图片，AI屈光医生已覆盖30余家医院。此外，AI质控系统日均质控病历超1万份，准确性超90%。
公司还积极推进眼科医疗大数据开发，整合66个高质量数据集，挂牌7款数据产品及4项数据知识产权，为未来AI商业化和行业标准制定奠定基础。
相关项目获得全国AI应用创新大赛二等奖、湖南省数字新基建百强项目等多项荣誉，提高了公司行业影响力和市场认可度。

2. 学科建设与临床能力提升

公司新设多个专业学组，强化亚专科和专病门诊建设，推进眼科全生命周期服务。引进全球前沿医疗设备与技术，如蔡司VISUMAX 800机器人全飞秒设备、SMILE pro微创手术、IGF-1R抗体药物（全球第二款）、干眼治疗新技术等，全面提升临床服务能力。
公司重视人才培养，全年引进和培养眼科专家、视光师、储备干部等1200余名，博士后工作站在站人员超40名。系列战略性培训计划累计覆盖5000余人次。

3. 科技创新平台与科研成果转化

2025年公司获批国家级及省部级科研项目67项，首次牵头国家AI医疗器械创新项目。报告期内，专家发表SCI/Medline论文144篇，其中多项研究发表于《Advanced Science》《The Lancet Regional Health – Western Pacific》《npj Digital Medicine》等国际权威期刊。
公司参与国际权威指南编撰，并联合中科院制定眼科大模型行业标准，引领行业AI技术和数据规范建设。

4. 医疗质量与患者服务体系优化

公司持续推进医疗质量与安全管理，构建标准化、精细化、智能化质控体系。AI质控门诊病历上线，35项核心制度实现系统化实时监测。
护理、药学、检验等专业线质控能力提升，新制定多项手术和质控标准。患者服务方面，推行“五心服务”标准化与数字化，全年组织服务培训68场，患者满意度达99.1%。

5. 组织变革与人才优化

公司全面调整总部及省区组织架构，合并多个省区为管理委员会，打破行政壁垒，提升运营效率。长沙医学中心升级为集团直管单元，整合临床与科研资源，打造世界级医学中心。
通过组织变革与人才强企战略，持续夯实高端人才队伍，为长期可持续发展提供保障。

四、股东与分红事项

• 拟按每10股派发现金红利1元（含税），不送股、不转增股。
• 公司控股股东为爱尔医疗投资集团有限公司（持股34.34%），陈邦为实际控制人。
• 前十大股东结构稳定，陈邦与郭宏伟为连襟关系，未发现其他关联关系。

五、可能影响股价的敏感事项与投资者须知

• 业绩分化：营业收入、门诊量、手术量稳健增长，但净利润出现下滑，特别是四季度利润大幅减少，表明公司在成本控制、利润释放方面存在压力，需密切关注未来盈利能力及成本结构调整。
• AI与数字化创新：公司在AI医疗领域处于行业领先地位，相关创新应用获得多项大奖及政策支持，有望推动公司估值提升及未来业绩释放。
• 组织结构调整：合并省区、成立管理委员会有助于提升运营效率，但短期内可能带来管理成本波动和变革风险。
• 高额现金分红：持续稳定分红显示公司现金流充沛，有利于提升投资者回报。
• 行业政策与监管：数字医疗、AI医疗监管政策变化或数据安全风险可能对公司未来发展产生重要影响，需投资者持续关注。

六、结论

爱尔眼科2025年以数字化和AI创新为主线推动高质量发展，核心业务规模保持扩张，医疗服务和科研创新能力持续提升。然而，净利润下滑及四季度业绩承压，需要投资者关注公司成本控制、盈利能力和变革成效。AI等创新战略的持续落地和行业地位提升，有望成为公司估值和股价新催化剂。

免责声明： 本文内容依据爱尔眼科2025年年度报告公开信息整理，仅供投资者参考，不构成任何投资建议。股市有风险，投资需谨慎。请结合自身风险承受能力做出投资决策。

English Version

In-depth Analysis of Aier Eye Hospital 2025 Annual Report: Digital Transformation and AI Drive Growth Amid Net Profit Pressure

Key Highlights of the Report

• Revenue up 6.53% YoY, but net profit attributable to shareholders down 8.88%
• Comprehensive push for digitalization and AI strategy, major breakthroughs in AI product matrix and medical big data development
• Outpatient and surgery volume continue to climb; “tiered chain” model deepens; overseas business expansion
• Dividend proposal: RMB 1 (tax included) cash dividend per 10 shares
• Organizational reform and talent structure optimization, with regional management committees for higher efficiency
• Multiple industry-first innovations and awards, significant enhancement in industry leadership

Core Performance and Financials

In 2025, Aier Eye Hospital achieved revenue of RMB 22.35 billion, up 6.53% year-on-year; outpatient visits reached 18.89 million, up 11.52%; surgeries totaled 1.68 million, up 5.77%. Despite steady business growth, net profit attributable to shareholders was RMB 3.24 billion, down 8.88% YoY; net profit excluding non-recurring items was RMB 3.14 billion, up 1.36% YoY.
Operating cash flow reached RMB 5.97 billion, up 22.35%. Total assets stood at RMB 36.68 billion, up 10.29%; net assets attributable to shareholders reached RMB 21.97 billion, up 6.08%.
Quarterly breakdown shows significant net profit decline in Q4, highlighting challenges in cost control and profit release, which investors should closely monitor.

Strategic Transformation & Innovation

1. Digitalization & AI Innovation—New Growth Drivers

Aier continued to invest in digital and AI innovation, building the “Aier AI Eye Hospital.” Core products like the AI fundus image diagnostic system have been called over 600,000 times; 30+ hospitals now use the AI refractive surgeon system, and AI-based quality control handles over 10,000 records daily with 90%+ accuracy.
The company is also actively developing ophthalmic medical big data, aggregating 66 high-quality datasets, listing 7 data products and 4 data IPs, laying the foundation for future AI commercialization and industry standard setting.
Projects won multiple national AI innovation awards and inclusion in key digital infrastructure programs, boosting industry influence and market recognition.

2. Discipline Building & Clinical Capability Enhancement

Multiple new specialist teams established; subspecialty clinics and disease-specific clinics expanded, providing full-cycle eye care. Advanced equipment and techniques imported, including Zeiss VISUMAX 800, SMILE pro, IGF-1R antibody drugs (world’s second approved), and new dry eye therapies, greatly improving clinical service quality.
Talent development remains a focus, with over 1,200 new hires and more than 40 postdocs in residency. Strategic training covered over 5,000 staff.

3. Technology Innovation Platform & Research Output

In 2025, Aier secured 67 national/provincial research projects, and for the first time led a national AI medical device innovation project. 144 SCI/Medline papers published, with research featured in Advanced Science, The Lancet Regional Health – Western Pacific, npj Digital Medicine, and more.
The company contributed to international guidelines and co-developed industry standards with the Chinese Academy of Sciences, leading ophthalmic AI and data standardization.

4. Medical Quality & Patient Service Optimization

Continuous improvement in medical quality and safety management; AI-based quality control systems now monitor 35 key metrics in real time. Nursing, pharmacy, and lab quality control also strengthened; several new surgery and QA standards released.
Patient service upgraded with the “Five-Heart” system, 68 training sessions held, and patient satisfaction reached 99.1%.

5. Organizational Reform & Talent Optimization

Aier restructured headquarters and regional units, merging multiple provinces into management committees to break administrative barriers and improve efficiency. Changsha Medical Center upgraded to a directly managed unit, integrating clinical and research resources.
Continuous talent strategy implementation ensures a strong pipeline for sustainable growth.

Shareholder & Dividend Matters

• Proposed RMB 1 (tax included) cash dividend per 10 shares. No stock bonus or capital increase.
• Controlling shareholder: Aier Medical Investment Group Co., Ltd. (34.34%); actual controller: Mr. Chen Bang.
• Top ten shareholders stable; no significant new related-party holdings.

Price-Sensitive Issues & Investor Alerts

• Performance divergence: While revenue, outpatient, and surgery volumes grew, net profit declined, especially in Q4. Investors should watch for cost control and margin improvement.
• AI/Digital innovation: Industry-leading AI healthcare initiatives and awards may serve as valuation catalysts when commercialized at scale.
• Organizational reform: Regional mergers and management restructuring may boost efficiency, but short-term transition risks exist.
• Stable dividend: Cash-rich business supports ongoing shareholder returns.
• Regulatory risks: Policy changes in digital and AI healthcare, or data security concerns, may impact future growth.

Conclusion

Aier Eye Hospital’s 2025 annual report shows robust expansion in core business and innovation leadership in digital/AI ophthalmology. However, falling net profit and Q4 earnings pressure require attention to cost management and transformation execution. AI and digital innovation successes may be key to future valuation uplift.

Disclaimer: This article is based on Aier Eye Hospital’s 2025 annual report for informational purposes only. It does not constitute investment advice. Please assess risks according to your own circumstances before making any investment decisions.

View 爱尔眼科 Historical chart here